Kiadis Pharma Initiates Collaboration for Personalized Immunotherapies using ATIRTM with Technische Universität München with­in Munich Biotech Cluster

Prof. Dr. Angela Krackhardt from the Klinikum rechts der Isar of the Technische Universität München to lead the project.

Amsterdam, The Netherlands, January 29, 2014 – Kiadis Pharma B.V., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing treat­ments for blood can­cers, today announces that it has ini­ti­at­ed a col­lab­o­ra­tion to iden­ti­fy and char­ac­ter­ize leukemia-spe­cif­ic T-cells in Kiadis Pharma’s lead prod­uct ATIRTM, that would be respon­si­ble for the Graft-ver­sus-Leukemia effect of the T-cell immunother­a­py prod­uct. The col­lab­o­ra­tion will be run with Prof. Dr. Angela Krackhardt who leads the group of Translational Immunotherapy at the Department of Hematology (Prof. Christian Peschel) of the Klinikum rechts der Isar of the Technische Universität München.
The project, which has now com­menced, was accept­ed by the Munich Biotech Cluster m4 and receives grant financ­ing from the Cluster for Prof. Krackhardt’s group. In the Munich Biotech Cluster, biotech­nol­o­gy com­pa­nies and aca­d­e­m­ic groups work togeth­er under the guid­ing con­cept of Personalised Medicine on about thir­ty research projects, in which new drugs and tech­nolo­gies are devel­oped.
ATIRTM is a T-cell based med­i­c­i­nal prod­uct that is cur­rent­ly in inter­na­tion­al mul­ti-cen­tre Phase II clin­i­cal tri­als as an adjunc­tive treat­ment after a T-cell deplet­ed hap­loiden­ti­cal stem cell trans­plan­ta­tion for patients for whom a match­ing donor can­not be found (in time). ATIRTM is man­u­fac­tured from lym­pho­cytes col­lect­ed from the same donor that pro­vides the graft for the stem cell trans­plan­ta­tion of the patient. ATIRTM is there­fore a tru­ly
per­son­al­ized immunother­a­py.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “We are delight­ed about our col­lab­o­ra­tion with the group of Prof. Krackhardt and being part of the Munich m4 Cluster fam­i­ly. We are con­fi­dent that this will expe­dite the iden­ti­fi­ca­tion of those T-cells in our lead prod­uct can­di­date, ATIR™, that are respon­si­ble for the Graft-ver­sus-Leukemia effect of the prod­uct. The Cluster’s exper­tise in immunother­a­pies and the trans­la­tion­al work of the University Clinic pro­vide the opti­mal basis for the suc­cess of this
Prof. Angela Krackhardt stat­ed: “We are pleased about the joint project with Kiadis Pharma. ATIR™ pro­vides us with the per­fect plat­form to iden­ti­fy (new) Graft-ver­sus-Leukemia T-cells. The pro­fi­cien­cy of Kiadis Pharma and our own well estab­lished exper­tise will result in a unique syn­er­gy.”

Leave a Reply

Your email address will not be published. Required fields are marked *